ClinicalTrials.gg
RecruitingNCT06789913Updated Nov 12, 2026

A Phase 2 Study of Mutant-selective PI3Kα Inhibitor, RLY-2608, in Adults and Children With PIK3CA Related Overgrowth Spectrum and Malformations Driven by PIK3CA Mutation (The ReInspire Study)

A Phase 2 interventional study of RLY-2608 and Placebo in PIK3CA-Related Overgrowth Spectrum (PROS), Lymphatic Malformations and Vascular Malformations, sponsored by Relay Therapeutics, Inc.. Recruiting at 46 sites in 10 countries. Open to participants aged 2 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.

Sponsored by Relay Therapeutics, Inc. · Phase 2, Interventional, and Treatment

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.
Updated Nov 12, 2026First site in Norway6 sites addedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
277
Allocation
Randomized
Ages
2 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 19 studies in Lymphatic Abnormalities with a site in United States — 7 open to participants now, 8 under way, 3 of them phase 3. Lymphatic Abnormalities · United States.

Planned enrollment
Largest of 16
277 · median 31
Started
2025
the only one that year
Phase 2
5 of 19
3 open now
Registered
17th of 19
by date

Among the 19 studies in Lymphatic Abnormalities with a site in United States, this one has the largest planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 5 in phase 2, and was the 17th registered.

Lymphatic Abnormalities

42 studies on the registry are indexed under Lymphatic Abnormalities; 17 are open to participants now.

Browse Lymphatic Abnormalities studies →

Open to participants now

7 of the 19 studies in Lymphatic Abnormalities with a site in United States are open now. Recruiting first, the newest first:

1 more — sign in →

All 7 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 14 Lymphatic Abnormalities studies recruiting now, 6 (43%) set no upper age limit and 5 (36%) stop at 75 or younger; 14 take children under 18; 1 takes healthy volunteers.

This study: 2 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Lymphatic Abnormalities with a site in United States, or all of them as a file.
02

Study summary

This is a 3-part Phase 2 randomized study evaluating the safety and efficacy of the mutant-selective PI3Kα inhibitor, zovegalisib (RLY-2608), in adults and children with PIK3CA Related Overgrowth Spectrum (PROS) and malformations driven by PIK3CA mutation. Part 1 is a dose selection, Part 2 is a basket design with exploratory single-arm cohorts for various subpopulations of participants, and Part 3 is randomized, double-blinded study vs placebo.

03

Conditions studied

  • PIK3CA-Related Overgrowth Spectrum (PROS)
  • Lymphatic Malformations
  • Vascular Malformations
  • PIK3CA Mutation
  • CLOVES Syndrome
  • Klippel Trenaunay Syndrome
  • Megalencephaly-capillary Malformation Polymicrogyria Syndrome (MCAP)
  • Vascular Anomalies
04

Who can participate

Ages eligible
2 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • The participant must have a clinical diagnosis of PROS or a malformation within the ISSVA classification.
  • One or more documented activating PIK3CA mutation(s) that are targeted by selective PI3Kα inhibitors in lesional tissue and/or cell-free DNA from the lesion or blood. Some participants may be eligible without a documented PIK3CA mutation, with the sponsor's approval, as long as no other genetic driver has been documented.
  • Lansky (\<16 yo) or (≥16 yo) performance status of ≥50.
  • Agree to provide archived lesional fluid and/or tissue or be willing to undergo pretreatment lesional (if considered safe and medically feasible) to assess PIK3CA status.

Key Exclusion Criteria:

  • Known to RLY-2608.
  • Any factors that increase the risk of prolongation or risk of arrhythmic events
  • , uncontrolled cardiovascular disease
  • Received disease-directed therapy prior to the first dose of study drug:

    1. Systemic therapy or antibody within 5 half-lives of the therapy.
    2. Local therapy including radiation, surgery, or other procedures within 28 days; lesion(s) must have demonstrated progression after the procedure.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Karnofsky performance status (KPS)

A 0–100 scale of how well someone can carry out everyday activities. 100 is no complaints and no signs of illness; 70 is able to look after yourself but not to work or keep up normal activity; 50 is needing considerable help and frequent medical care.

Studies often ask for 60 or 70 and above. Your doctor gives the score.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
277 participants (estimated)

Study arms

  • Experimental
    Part 1, Group 1

    RLY-2608 for patients ≥12 years old with PROS or malformations with PIK3CA mutation. Multiple doses of RLY-2608 for oral administration.

    Drug: RLY-2608

  • Experimental
    Part 1, Group 2

    RLY-2608 for participants 6 to \<12 years old with PROS or malformations with PIK3CA mutation. RLY-2608 will be studied in pediatric participants in a dose escalation design.

    Drug: RLY-2608

  • Experimental
    Part 1, Group 3

    Part 1, Group 3: RLY-2608 for participants 2 to \<6 years old with PROS or malformations with PIK3CA mutation. RLY-2608 will be studied in pediatric participants in a dose escalation design.

    Drug: RLY-2608

  • Experimental
    Part 2, Group 1

    Dose expansion single-arm cohorts for various subpopulations of participants ≥12 years old with PROS or malformations with PIK3CA mutation. Oral dose of RLY-2608 as determined during Part 1.

    Drug: RLY-2608

  • Experimental
    Part 2, Group 2

    Dose expansion cohorts for participants 6 to \<12 years old with PROS or malformations with PIK3CA mutation. Oral dose of RLY-2608 as determined during Part 1.

    Drug: RLY-2608

  • Experimental
    Part 2, Group 3

    Dose expansion cohorts for participants 2 to \<6 years old with PROS or malformations with PIK3CA mutation. Oral dose of RLY-2608 as determined during Part 1.

    Drug: RLY-2608

  • Experimental
    Part 3, Arm 1

    Adult (\>18 yo) and pediatric (6 to \<18 yo) participants with PROS and malformations with PIK3CA mutation will be randomized to receive RLY-2608 at oral dose determined during Part 1/2.

    Drug: RLY-2608

  • Placebo comparator
    Part 3, Arm 2

    Adult (\>18 yo) and pediatric (6 to \<18 yo) participants with PROS and malformations with PIK3CA mutation will be randomized to receive placebo.

    Drug: Placebo

Interventions

  • DrugRLY-2608

    RLY-2608 is a mutant-selective, oral PI3Kα inhibitor.

  • DrugPlacebo

    RLY-2608 matched-placebo

06

What researchers measure

Primary outcomes

  1. Parts 1 and 2: Determination of a recommended phase 2 dose RP2D(s) for Groups 1, 2, and 3

    Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation

  2. Parts 1 and 2: Occurrence/frequency of Adverse Events (AEs), changes in vital signs, ECGs, and safety laboratory tests and their relationship to the study drugs (safety and tolerability).

    Time frame: Cycle 1 of treatment and at the end of every cycle until study discontinuation

  3. Part 3: Percentage of participants with volumetric Response.

    Time frame: Baseline, Week 24

Secondary outcomes

  1. Part 1 and 2: Percent change from baseline in lesion volume

    Time frame: Baseline, Week 24

  2. Part 1 and 2: Duration of response, defined as the time of first documented response to the date of first documented disease progression or death due to any cause

    Time frame: Approximately every 3 months for approximately the first year, and then every 6 months during treatment

  3. Part 1 and 2: Percentage of participants with volumetric response

    Time frame: Baseline, week 12, week 24

  4. Part 1 and 2: Plasma concentrations and PK parameters of RLY-2608

    Time frame: Approximately every 2 weeks in Cycle 1, then again at Cycles 2, 4 and Cycle 7 depending on the participant's group

  5. Part 1 and 2: PIK3CA mutational status in lesional fluid and/or tissue

    Time frame: Prior to enrollment

  6. Part 3: Percentage of participants with improvement compared to baseline based on PGI-S, PGI-C and IGIC

    Time frame: Approximately once a month until end of treatment

  7. Part 3: Change from baseline by age-appropriate PROMIS Profile

    Time frame: Approximately once a month until end of treatment

  8. Part 3: Change from baseline in EQ-5D, EQ-5D-Y, or EQ-5D-Y Proxy

    Time frame: Approximately once a month until end of treatment

  9. Part 3: Percent change from baseline in lesion volume

    Time frame: Approximately every 3 months for approximately the first year, and then every 6 months during treatment

07

Study locations

46 of 46 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jun 2025 (actual). Primary completion is estimated for Jul 2031, 73 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 17, 2025
First posted
Jan 23, 2025
StartActual
Jun 13, 2025
Primary completionEst.
Jul 2031
CompletionEst.
Oct 2031
Last update
Nov 12, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
6 sites added — first site in Norway
Show 6 added (3 France, 1 United States, 1 Australia, 1 Norway)
  • University of Missouri · Columbia, United States
  • The Skin Hospital · Sydney, Australia
  • CHU Amiens · Amiens, France
  • CHU de Bordeaux · Bordeaux, France
  • Hôpital de la Timone · Marseille, France
  • Oslo University Hospital · Oslo, Norway
Nov 12, 2026
Show all 1 update
  1. Nov 12, 2026
    6 sites added — first site in Norway
    Show 6 added (3 France, 1 United States, 1 Australia, 1 Norway)
    • University of Missouri · Columbia, United States
    • The Skin Hospital · Sydney, Australia
    • CHU Amiens · Amiens, France
    • CHU de Bordeaux · Bordeaux, France
    • Hôpital de la Timone · Marseille, France
    • Oslo University Hospital · Oslo, Norway

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06789913
Lead sponsor
Relay Therapeutics, Inc.
Responsible party
Sponsor
First posted
Jan 23, 2025
Start date
Jun 13, 2025
Primary completion
Jul 2031 (estimated)
Completion
Oct 2031 (estimated)
Last update
Nov 12, 2026

Study contacts

Relay Therapeutics, Inc
Contact
ClinicalTrials@relaytx.com
617-322-0731

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion